Press Releases

Research and Markets: Melanoma - Thought Leader Panel 2012 - A Summary of Perspectives from 6 Renowned US and European Thought Leaders

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Melanoma - Thought Leader Panel 2012" report to their offering.

Hematology/Oncology Panel #31 summarizes the perspectives of six renowned US and European Thought Leaders who specialize in the treatment of melanoma. All were interviewed in the days following ASCO 2012 Chicago. It is unusual for two consecutive ASCOs to be dominated by advances in the same disease, but new checkpoint inhibitors and next generation targeted therapies were the highlights of this meeting, just as ipilimumab and vemurafenib were at ASCO 2011.

Coming out of ASCO there remain a series of important questions that the melanoma community still needs to address. The purpose of this Panel was to give our Thought Leaders to expand upon the discussions that we heard at ASCO and share their current perspectives on:

- Immunotherapy vs BRAFi first-line

- Immunotherapy + BRAFi

- Treatment of BRAFi resistance

- Prevention of BRAFi resistance

- Adjuvant therapy

- Role of multi TKI inhibitors

- Role of chemotherapy

- Uncommon BRAF mutations

- NRAS mutants with MAPK dependency

The Panel discusses monotherapies and combinations that mix and match inhibition (or activation) of BRAF, MEK, PI3K/MTOR/AKT, NRAS, cKIT, CTLA4, PD1, PDL1, MICA, TIM3, IDO, MET, VEGF, IL2, IFN and chemotherapy.

Companies/Compounds Discussed in This Report:


- Yervoy (ipilimumab; Bristol-Myers Squibb)

- tremelimumab (Pfizer)

- gp100: 209-217(210M) peptide (NIH)

- Proleukin (aldesleukin; IL-2; Prometheus)

- GSK2132231A MAGE-A3 (GlaxoSmithKline)

- BMS-936558/MDX-1106/ONO-4538 (anti-PD-1 antibody; Medarex / Bristol-Myers Squibb / Ono)

- MDX-1105/BMS-936559 (BMS)

- MK-3475/SCH 900475 (Merck)

- AMP-224 (Amplimmune / GlaxoSmithKline)

- MPDL3280A (Roche / Genentech)

- CT-011 (CureTech)

- Micacide (AvidBiotics)

- TIM3 antibodies (Brigham & Women's)

- INCB242360 (Incyte)

- Interferon adjuvant biochemotherapy (cisplatin, vinblastine, DTIC, IL-2, IFN)


- Zelboraf / vemurafenib / RO5185426 / PLX-4032/RG-7204 (Plexxikon / Roche)

- dabrafenib / GSK2118436 (GlaxoSmithKline)

- BMS908662 / XL-281 (Bristol-Myers Squibb; Exelixis)


- trametinib / GSK1120212 (GSK)

- GDC-0973 (Genentech / Exelixis)

- RO4987655 (Roche)

- selumetinib (AstraZeneca)

- pimasertib MSC1936369B (Merck Serono / Sanofi-Aventis)

- MEK-162 / ARRY-162 (Novartis / Array)

- TAK-733 (Takeda)

- MSC1936369B (EMD Serono)


- GSK2110183 (AKT GSK)

- MK-2206 (AKT Merck)

- GSK2126458 (PI3K GSK)

- GDC-0941 (Genentech)

- BKM-120 (Novartis)

- BEZ-235 (Novartis)

- SAR245409 (XL765) (Sanofi-Aventis / Exelixis)


- Avastin (bevacizumab; Genentech)

- Nexavar (sorafenib; Bayer-Schering / Onyx)

- axitinib (Pfizer)

- Zaltrap (aflibercept; VEGF Trap; Sanofi-Aventis / Regeneron)

- lenvatinib (E-7080; Eisai)


- tivantinib / ARQ-197 (ArQule / Daiichi-Sankyo)

- cabozantinib; XL-184 (Exelixis)


- Temodar (temozolomide; Bayer-Schering)

- Abraxane NAB-paclitaxel (Celgene)


- Tasigna (nilotinib; Novartis)

- Gleevec (imatinib; Novartis)

- Sutent (sunitinib; Pfizer)

For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets